Showing results (361-370 of 372) with videos related to
Sort By:
Pageof 38
Journal of Medicinal Chemistry|August 24, 2000
Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET(A) antagonistsN Murugesan, Z Gu, P D Stein, et al.The Journal of Pain|March 17, 2022
Confronting Racism in All Forms of Pain Research: Reframing Study DesignsJanelle E Letzen, Vani A Mathur, Mary R Janevic, et al.BMJ Open|October 2, 2014
Does a 'direct' transfer protocol reduce time to coronary angiography for patients with non-ST-elevation acute coronary syndromes? A prospective observational studyS M Gallagher, M J Lovell, D A Jones, et al.Heart (British Cardiac Society)|December 1, 2011
Case fatality rates for South Asian and Caucasian patients show no difference 2.5 years after percutaneous coronary interventionD A Jones, K S Rathod, N Sekhri, et al.The Journal of Pharmacology and Experimental Therapeutics|October 19, 1999
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosisM W Lark, G B Stroup, S M Hwang, et al.Journal of Environmental Management|June 1, 2021
Energy and carbon budgeting of traditional land use change with groundnut based cropping system for environmental quality, resilient soil health and farmers income in eastern Indian HimalayasM A Ansari, Saurav Saha, Anup Das, et al.Infection|October 2, 2015
Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory responseJ M Bordon, R Fernandez-Botran, T L Wiemken, et al.Journal of Medicinal Chemistry|November 2, 2001
Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockersJ Lloyd, J B Schmidt, G Rovnyak, et al.Journal of Medicinal Chemistry|December 19, 1998
Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of the orally active endothelin antagonist 2'-amino-N- (3,4-dimethyl-5-isoxazolyl)-4'-(2-methylpropyl)[1, 1'-biphenyl]-2-sulfonamide (BMS-187308)N Murugesan, Z Gu, P D Stein, et al.Bioorganic & Medicinal Chemistry Letters|November 21, 2001
BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptorA V Gavai, P M Sher, A B Mikkilineni, et al.Pageof 38